PT - JOURNAL ARTICLE AU - RL Winslow AU - J Zhou AU - EF Windle AU - I Nur AU - R Lall AU - C Ji AU - JE Millar AU - P Dark AU - J Naisbitt AU - A Simonds AU - J Dunning AU - W Barclay AU - K Baillie AU - GD Perkins AU - MG Semple AU - DF McAuley AU - CA Green TI - SARS-CoV-2 environmental contamination from hospitalised COVID-19 patients receiving aerosol generating procedures AID - 10.1101/2021.07.04.21259945 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.04.21259945 4099 - http://medrxiv.org/content/early/2021/07/08/2021.07.04.21259945.short 4100 - http://medrxiv.org/content/early/2021/07/08/2021.07.04.21259945.full AB - Background Continuous positive airways pressure (CPAP) and high-flow nasal oxygen (HFNO) are considered ‘aerosol-generating procedures’ (AGPs) in the treatment of COVID-19. We aimed to measure air and surface environmental contamination of SARS-CoV-2 virus when CPAP and HFNO were used, compared with supplemental oxygen, to investigate the potential risks of viral transmission to healthcare workers and patients.Methods 30 hospitalised patients with COVID-19 requiring supplemental oxygen, with a fraction of inspired oxygen ≥0.4 to maintain oxygen saturations ≥94%, were prospectively enrolled into an observational environmental sampling study. Participants received either supplemental oxygen, CPAP or HFNO (n=10 in each group). A nasopharyngeal swab, three air and three surface samples were collected from each participant and the clinical environment. RT qPCR analyses were performed for viral and human RNA, and positive/suspected-positive samples were cultured for the presence of biologically viable virus.Results Overall 21/30 (70%) of participants tested positive for SARS-CoV-2 RNA in the nasopharynx. In contrast, only 4/90 (4%) and 6/90 (7%) of all air and surface samples tested positive (positive for E and ORF1a) for viral RNA respectively, although there were an additional 10 suspected-positive samples in both air and surfaces samples (positive for E or ORF1a). CPAP/HFNO use or coughing was not associated with significantly more environmental contamination. Only one nasopharyngeal sample was culture positive.Conclusions The use of CPAP and HFNO to treat moderate/severe COVID-19 was not associated with significantly higher levels of air or surface viral contamination in the immediate care environment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis report is independent research funded by the National Institute for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. The University of Oxford is the Sponsor for the ISARIC WHO CCP-UK protocol.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval Oxford C Research Ethics Committee (13/SC/0149).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available to researchers on request subject to sponsor approval.